Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on August 30, 2021. The report details corporate governance changes, specifically the appointment of a new director and an amendment to the company's by-laws regarding board size.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
- Board Appointment: Patricia P. Gonzalez was named to the Abbott Laboratories Board of Directors on August 30, 2021.
- By-Law Amendment: The Board amended Article III, Section 2 of the by-laws to increase the number of directors from thirteen to fourteen, effective August 30, 2021.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the professional background and qualifications of the newly appointed director, Patricia P. Gonzalez.
- Confirm the effective date of the by-law amendment increasing the Board size to fourteen members.
- Review the attached Exhibit 3.1 for the full text of the amended and restated By-Laws.